Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19064634 | 0.85 | POLB (0.65) | POLBSMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL20119352 | 0.81 | SMN1; SMN2 (0.59) | POLBSMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL17009430 | 0.79 | POLB (1.00) | POLBSMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL17443015 | 0.79 | APP (0.62) | KMT2AMAPTLMNAKDM4EPKM | |
| SCHEMBL20119401 | 0.78 | SMN1; SMN2 (0.53) | POLBSMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL30455170 | 0.77 | PDE5A (0.70) | POLBSMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL21460561 | 0.77 | PDE5A (0.70) | POLBSMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL17933811 | 0.77 | SMN1; SMN2 (0.55) | POLBSMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL24645842 | 0.76 | PDE2A (0.57) | POLBSMN1; SMN2MAPTLMNAHTT | |
| SCHEMBL29795378 | 0.76 | PDE2A (0.57) | POLBSMN1; SMN2MAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4115882-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| EP-3104706-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2016115434-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2015123365-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ LLC (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | POLB 989/4885SMN1; SMN2 11/4885KMT2A 2971/4885 |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | POLB 320/4885SMN1; SMN2 106/4885KMT2A 3495/4885 |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, PDF | POLB 416/4885SMN1; SMN2 7/4885KMT2A 3986/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | POLB 989/4885SMN1; SMN2 11/4885KMT2A 2971/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | POLB 989/4885SMN1; SMN2 11/4885KMT2A 2971/4885 |
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | POLB 260/4885SMN1; SMN2 105/4885KMT2A 3805/4885 |
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | POLB 320/4885SMN1; SMN2 106/4885KMT2A 3495/4885 |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | POLB 320/4885SMN1; SMN2 106/4885KMT2A 3495/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | POLB 989/4885SMN1; SMN2 11/4885KMT2A 2971/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | POLB 989/4885SMN1; SMN2 11/4885KMT2A 2971/4885 |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | POLB 285/4885SMN1; SMN2 87/4885KMT2A 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.